These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 39487715)

  • 1. Real-World Experience of 3-Year Treatment With Dupilumab: Significant Decrease in Circulating Neutrophils and Eosinophils in Japanese Patients With Atopic Dermatitis.
    Nakajima H; Kamata M; Okada Y; Suzuki S; Ito M; Watanabe A; Egawa S; Chijiwa C; Hiura A; Tomura Y; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Tada Y
    Exp Dermatol; 2024 Nov; 33(11):e70010. PubMed ID: 39487715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial.
    Simpson EL; Silverberg JI; Thyssen JP; Viguier M; Thaçi D; de Bruin-Weller M; Weidinger S; Chan G; DiBonaventura M; Biswas P; Feeney C; Koulias C; Cork MJ
    Am J Clin Dermatol; 2023 Jul; 24(4):609-621. PubMed ID: 37213005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dupilumab treatment ameliorates clinical and hematological symptoms, including blood eosinophilia, in patients with atopic dermatitis.
    Yamauchi T; Sasaki S; Lee ES; Tamura T; Seki M; Miwa T; Kobayashi K; Saruta Y; Kitami Y; Sueki H; Watanabe H
    Int J Dermatol; 2021 Feb; 60(2):190-195. PubMed ID: 32989751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
    Blauvelt A; Guttman-Yassky E; Paller AS; Simpson EL; Cork MJ; Weisman J; Browning J; Soong W; Sun X; Chen Z; Kosloski MP; Kamal MA; Delevry D; Chuang CC; O'Malley JT; Bansal A
    Am J Clin Dermatol; 2022 May; 23(3):365-383. PubMed ID: 35567671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis.
    Paller AS; Pinter A; Wine Lee L; Aschoff R; Zdybski J; Schnopp C; Praestgaard A; Bansal A; Shumel B; Prescilla R; Bastian M
    Adv Ther; 2024 Mar; 41(3):1046-1061. PubMed ID: 38194047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploration of biomarkers to predict clinical improvement of atopic dermatitis in patients treated with dupilumab: A study protocol.
    Nakahara T; Izuhara K; Onozuka D; Nunomura S; Tamagawa-Mineoka R; Masuda K; Ichiyama S; Saeki H; Kabata Y; Abe R; Ohtsuki M; Kamiya K; Okano T; Miyagaki T; Ishiuji Y; Asahina A; Kawasaki H; Tanese K; Mitsui H; Kawamura T; Takeichi T; Akiyama M; Nishida E; Morita A; Tonomura K; Nakagawa Y; Sugawara K; Tateishi C; Kataoka Y; Fujimoto R; Kaneko S; Morita E; Tanaka A; Hide M; Aoki N; Sano S; Matsuda-Hirose H; Hatano Y; Takenaka M; Murota H; Katoh N; Furue M
    Medicine (Baltimore); 2020 Sep; 99(38):e22043. PubMed ID: 32957324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Effectiveness of Dupilumab in Adult and Adolescent Patients with Atopic Dermatitis: 2-Year Interim Data from the PROSE Registry.
    Simpson EL; Lockshin B; Lee LW; Chen Z; Daoud M; Korotzer A
    Dermatol Ther (Heidelb); 2024 Jan; 14(1):261-270. PubMed ID: 38175364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Possibility of maintaining remission with topical therapy alone after withdrawal of dupilumab in Japanese patients with atopic dermatitis and their characteristics in the real world.
    Watanabe A; Kamata M; Okada Y; Suzuki S; Ito M; Uchida H; Chijiwa C; Egawa S; Hiura A; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Tada Y
    Exp Dermatol; 2024 Sep; 33(9):e15175. PubMed ID: 39277874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials.
    Silverberg JI; Simpson EL; Ardeleanu M; Thaçi D; Barbarot S; Bagel J; Chen Z; Eckert L; Chao J; Korotzer A; Rizova E; Rossi AB; Lu Y; Graham NMH; Hultsch T; Pirozzi G; Akinlade B
    Br J Dermatol; 2019 Jul; 181(1):80-87. PubMed ID: 30791102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association study of transition of laboratory marker levels and transition of disease activity of atopic dermatitis patients treated with dupilumab.
    Mizuno M; Horiguchi G; Teramukai S; Ichiyama S; Ito M; Hoashi T; Kanda N; Saeki H
    Australas J Dermatol; 2021 Nov; 62(4):e504-e509. PubMed ID: 34523731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study.
    Paller AS; Siegfried EC; Simpson EL; Cork MJ; Sidbury R; Chen IH; Khokhar FA; Xiao J; Dubost-Brama A; Bansal A
    Am J Clin Dermatol; 2024 Jul; 25(4):655-668. PubMed ID: 38743155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Effectiveness and Reasons for Discontinuation of Dupilumab in Patients With Atopic Dermatitis.
    Boesjes CM; Kamphuis E; de Graaf M; Spekhorst LS; Haeck I; van der Gang LF; Loman L; Zuithoff NPA; Dekkers C; van der Rijst LP; Romeijn GLE; Oosting AJ; Gostynksi A; van Lynden-van Nes AMT; Tupker RA; van Tuyll van Serooskerken AM; Flinterman A; Politiek K; Touwslager WRH; Christoffers WA; Stewart SM; Kamsteeg M; Schuttelaar MA; de Bruin-Weller MS
    JAMA Dermatol; 2024 Oct; 160(10):1044-1055. PubMed ID: 39110432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Dupilumab in Chinese Elderly Patients with Atopic Dermatitis: A Real-World Study.
    Hu YQ; Zhang JZ; Zhao Y
    Dermatology; 2024; 240(4):589-596. PubMed ID: 38797168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher baseline serum lactate dehydrogenase level is associated with poor effectiveness of dupilumab in the long term in patients with atopic dermatitis.
    Kato A; Kamata M; Ito M; Uchida H; Nagata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
    J Dermatol; 2020 Sep; 47(9):1013-1019. PubMed ID: 32548920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
    Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A
    Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weight gain in patients with severe atopic dermatitis treated with dupilumab: a cohort study.
    Johansson EK; Ivert LU; Bradley B; Lundqvist M; Bradley M
    BMC Dermatol; 2020 Sep; 20(1):8. PubMed ID: 32962676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of atopic dermatitis with dupilumab: experience from a tertiary referral centre.
    Olesen CM; Holm JG; Nørreslet LB; Serup JV; Thomsen SF; Agner T
    J Eur Acad Dermatol Venereol; 2019 Aug; 33(8):1562-1568. PubMed ID: 30959559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment outcomes of patients with Atopic Dermatitis (AD) treated with dupilumab through the Early Access to Medicines Scheme (EAMS) in the UK.
    O'Kane D; Davis L; Ardern-Jones M; Laws P; Shaw L; Cork M; Velangi S; Cooper HL; Hudson R; Smith AB; Rout R
    Ulster Med J; 2021 May; 90(2):70-76. PubMed ID: 34276083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dupilumab Improves Clinical Scores in Children and Adolescents With Moderate to Severe Atopic Dermatitis: A Real-World, Single-Center Study.
    Pagan AD; David E; Ungar B; Ghalili S; He H; Guttman-Yassky E
    J Allergy Clin Immunol Pract; 2022 Sep; 10(9):2378-2385. PubMed ID: 35753667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 Trials.
    Alexis AF; Rendon M; Silverberg JI; Pariser DM; Lockshin B; Griffiths CE; Weisman J; Wollenberg A; Chen Z; Davis JD; Li M; Eckert L; Gadkari A; Shumel B; Rossi AB; Graham NM; Ardeleanu M
    J Drugs Dermatol; 2019 Aug; 18(8):804-813. PubMed ID: 31424712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.